6-Fluoro-α-methyltryptamine (6-fluoro-AMT, 6F-AMT) is a tryptamine derivative related to compounds such as α-methyltryptamine (AMT) and 5-MeO-AMT which has been sold as a designer drug.[1][2]
Clinical data | |
---|---|
Other names | 6-Fluoro-AMT; 6-Fluoro-αMT; 6F-AMT; 6F-αMT; 6-F-AMT; 6-F-αMT |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H13FN2 |
Molar mass | 192.237 g·mol−1 |
3D model (JSmol) | |
| |
|
Animal tests showed the drug to be somewhat less potent in terms of pharmacological activity than AMT or 5-fluoro-AMT.[3] It produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.[4][5][6] Its IC50 for monoamine oxidase A (MAO-A) inhibition is 580 to 1,800 nM, compared to 180 to 450 nM for 5-fluoro-AMT and 380 nM for AMT.[5][7][8]
6-Fluoro-AMT was allegedly manufactured and sold from the laboratory operated by Leonard Pickard and Gordon Todd Skinner, who described 6-fluoro-AMT as "a beast".[1] In interviews, Skinner stated that he first began to experiment with 6-fluoro-AMT in the early 1980s by giving it to high school friends.[2] Their experiences made him cautious about the appropriate doses, which he said ranged from 25 to 75 mg (Skinner weighed about 250 lbs at the time of his own bioassay).[2] Skinner said that 6-fluoro-AMT is a long-lasting psychedelic with more time distortion and that it was enhanced by combination with ALD-52.[2]
See also
editReferences
edit- ^ a b Morris H (2010). "Life is a Cosmic Giggle on the Breath of the Universe. A Tour of Gordon Todd Skinner's Subterranean LSD Palace". Vice Magazine. Archived from the original on 2014-10-13. Retrieved 2017-08-23.
- ^ a b c d "Unusual Analogues: Drugs Used by Gordon Todd Skinner". thislandpress.com. This Land Press. Retrieved 8 April 2016.
- ^ Kalir A, Szara S (November 1963). "Synthesis and Pharmacological Activity of Fluorinated Tryptamine Derivatives". Journal of Medicinal Chemistry. 6 (6): 716–719. doi:10.1021/jm00342a019. PMID 14184932.
- ^ Halberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior". Curr Top Behav Neurosci. 36: 159–199. doi:10.1007/7854_2016_466. PMC 5787039. PMID 28224459.
- ^ a b Nakagawasai O, Arai Y, Satoh SE, Satoh N, Neda M, Hozumi M, Oka R, Hiraga H, Tadano T (January 2004). "Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives". Neurotoxicology. 25 (1–2): 223–232. doi:10.1016/S0161-813X(03)00101-3. PMID 14697897.
- ^ Tadano T, Neda M, Hozumi M, Yonezawa A, Arai Y, Fujita T, Kinemuchi H, Kisara K (February 1995). "alpha-Methylated tryptamine derivatives induce a 5-HT receptor-mediated head-twitch response in mice". Neuropharmacology. 34 (2): 229–234. doi:10.1016/0028-3908(94)00119-d. PMID 7617148.
- ^ Wagmann L, Brandt SD, Kavanagh PV, Maurer HH, Meyer MR (April 2017). "In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks". Toxicol Lett. 272: 84–93. doi:10.1016/j.toxlet.2017.03.007. PMID 28302559.
- ^ "Advantageous tryptamine compositions for mental disorders or enhancement". Google Patents. 20 September 2021. Retrieved 8 December 2024.